CLOSED
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglut. Track EMCURE PHARMACEUTICALS L's live NSE:EMCURE share price ₹1,972.10 (+0.61%), market cap ₹₹374B, P/E 40.4. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for EMCURE — real-time NSE India stock intelligence.
Open
₹1,966.00
High
₹1,996.70
Low
₹1,933.10
Prev. Close
₹1,960.10
52W High
₹1,960.00
52W Low
₹1,260.00
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglut
Key Takeaway
EMCURE PHARMACEUTICALS L is rated strong buy with a P/E of 40.4x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is EMCURE PHARMACEUTICALS L fairly valued right now?
Because a P/E of 40.4x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting EMCURE PHARMACEUTICALS L
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
2,470 Cr
Revenue
243 Cr
Net Profit
19.6%
ROE
0%
ROCE
48.81
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 5,931 | 6,582 | 7,896 | 9,204 | 9,204 |
| Net Profit | 532 | 498 | 681 | 924 | 924 |
| ROE (%) | — | — | — | 19.6% | 19.6% |
| EPS (₹) | — | — | — | 48.81 | 48.81 |
| Debt/Equity | — | — | — | 30.6 | 30.6 |